Published in Cancer Res on June 15, 2008
Inherited determinants of ovarian cancer survival. Clin Cancer Res (2010) 1.32
New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am (2011) 1.31
HSulf-1 modulates FGF2- and hypoxia-mediated migration and invasion of breast cancer cells. Cancer Res (2011) 1.09
Systemic VHL gene functions and the VHL disease. FEBS Lett (2012) 0.94
Complex cellular functions of the von Hippel-Lindau tumor suppressor gene: insights from model organisms. Oncogene (2011) 0.92
Effects of membrane trafficking on signaling by receptor tyrosine kinases. Cold Spring Harb Perspect Biol (2013) 0.87
Hypoxia negatively regulates heparan sulfatase 2 expression in renal cancer cell lines. Mol Carcinog (2011) 0.85
The role of ets factors in tumor angiogenesis. J Oncol (2010) 0.85
Drosophila von Hippel-Lindau tumor suppressor gene function in epithelial tubule morphogenesis. Mol Cell Biol (2010) 0.82
Drosophila VHL tumor-suppressor gene regulates epithelial morphogenesis by promoting microtubule and aPKC stability. Development (2010) 0.82
Tie2-dependent VHL knockdown promotes airway microvascular regeneration and attenuates invasive growth of Aspergillus fumigatus. J Mol Med (Berl) (2013) 0.81
Interaction between Nm23 and the tumor suppressor VHL. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.76
Von Hippel-Lindau disease (VHL): a need for a murine model with retinal hemangioblastoma. Histol Histopathol (2012) 0.75
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 23.45
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (1993) 11.95
Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science (1999) 6.38
von Hippel-Lindau disease. Lancet (2003) 6.20
Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer (2002) 5.63
Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol (2003) 5.14
Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci U S A (2001) 4.60
Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol (2006) 4.47
Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci U S A (2000) 4.41
Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci U S A (1999) 3.43
Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol (2003) 3.37
Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci U S A (1997) 3.27
The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev (1999) 3.17
Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res (2003) 2.93
A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell (2002) 2.88
Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Mol Cell Biol (1996) 2.79
The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell (1998) 2.77
Signal transduction and the Ets family of transcription factors. Oncogene (2000) 2.23
Regulation of receptor tyrosine kinase signaling by endocytic trafficking. Traffic (2001) 1.89
A simple immunomagnetic protocol for the selective isolation and long-term culture of human dermal microvascular endothelial cells. Exp Cell Res (1998) 1.81
von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol (1997) 1.74
The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol (1999) 1.62
Isolation, culture, and characterization of endothelial cells from mouse glomeruli. Kidney Int (2004) 1.48
c-ets1 proto-oncogene is a transcription factor expressed in endothelial cells during tumor vascularization and other forms of angiogenesis in humans. Am J Pathol (1992) 1.33
VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol Cell Biol (2001) 1.31
Fibroblast-dependent differentiation of human microvascular endothelial cells into capillary-like 3-dimensional networks. FASEB J (2002) 1.31
VHL gene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma. Arch Ophthalmol (1999) 1.31
Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. Am J Nephrol (2003) 1.23
Drosophila awd, the homolog of human nm23, regulates FGF receptor levels and functions synergistically with shi/dynamin during tracheal development. Genes Dev (2003) 1.22
Multitasking by pVHL in tumour suppression. Curr Opin Cell Biol (2007) 1.21
pVHL function is essential for endothelial extracellular matrix deposition. Mol Cell Biol (2006) 1.18
Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility. J Biol Chem (2006) 1.13
von Hippel-Lindau protein promotes the assembly of actin and vinculin and inhibits cell motility. Cancer Res (2001) 1.11
Evolution of VHL tumourigenesis in nerve root tissue. J Pathol (2006) 1.11
Von Hippel-Lindau disease: the recognition and treatment of early angiomatosis retinae and the use of cryosurgery as an adjunct to therapy. Trans Am Ophthalmol Soc (1970) 1.08
Susceptibility to vascular neoplasms but no increased susceptibility to renal carcinogenesis in Vhl knockout mice. Carcinogenesis (2003) 1.08
Tracheal development and the von Hippel-Lindau tumor suppressor homolog in Drosophila. Oncogene (2000) 0.98
VHL mutation analysis in patients with isolated central nervous system haemangioblastoma. Brain (2007) 0.97
Phosphorylation of Ets1 regulates the complementation of a CSF-1 receptor impaired in mitogenesis. Oncogene (1996) 0.96
Effects of epidermal growth factor, fibroblast growth factor, and transforming growth factor-beta on corneal cell chemotaxis. Invest Ophthalmol Vis Sci (1992) 0.94
Expression of an Ets-1 dominant-negative mutant perturbs normal and tumor angiogenesis in a mouse ear model. Oncogene (2003) 0.93
Drosophila dopamine synthesis pathway genes regulate tracheal morphogenesis. Dev Biol (2007) 0.92
Cyr61/CCN1 and CTGF/CCN2 mediate the proangiogenic activity of VHL-mutant renal carcinoma cells. Carcinogenesis (2008) 0.91
Vascular endothelial growth factor promotes proliferation and migration of cavernous smooth muscle cells. J Urol (2001) 0.83
Anti-angiogenic therapy in renal cell cancer. BJU Int (2007) 0.80
Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma. World J Urol (2007) 0.80
Isolation and molecular characterization of a mouse renal microvascular endothelial cell line. In Vitro Cell Dev Biol Anim (2004) 0.79
RNA-dependent integrin alpha3 protein localization regulated by the Muscleblind-like protein MLP1. Nat Cell Biol (2005) 1.57
Site-directed mutagenesis using Pfu DNA polymerase and T4 DNA ligase. Biotechniques (2005) 1.30
Drosophila awd, the homolog of human nm23, regulates FGF receptor levels and functions synergistically with shi/dynamin during tracheal development. Genes Dev (2003) 1.22
Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility. J Biol Chem (2006) 1.13
Opposite effects of dihydrosphingosine 1-phosphate and sphingosine 1-phosphate on transforming growth factor-beta/Smad signaling are mediated through the PTEN/PPM1A-dependent pathway. J Biol Chem (2008) 1.06
Analysis of the hypoxia-sensing pathway in Drosophila melanogaster. Biochem J (2006) 1.01
Caspase-1 is a direct target gene of ETS1 and plays a role in ETS1-induced apoptosis. Cancer Res (2005) 0.96
Systemic VHL gene functions and the VHL disease. FEBS Lett (2012) 0.94
Awd, the homolog of metastasis suppressor gene Nm23, regulates Drosophila epithelial cell invasion. Mol Cell Biol (2008) 0.93
dAkt kinase controls follicle cell size during Drosophila oogenesis. Dev Dyn (2005) 0.93
The Drosophila metastasis suppressor gene Nm23 homolog, awd, regulates epithelial integrity during oogenesis. Mol Cell Biol (2009) 0.92
Developmental function of Nm23/awd: a mediator of endocytosis. Mol Cell Biochem (2009) 0.92
Drosophila dopamine synthesis pathway genes regulate tracheal morphogenesis. Dev Biol (2007) 0.92
Coordinated functions of Akt/PKB and ETS1 in tubule formation. FASEB J (2003) 0.92
The Drosophila zinc finger transcription factor CF2 is a myogenic marker downstream of MEF2 during muscle development. Mech Dev (2002) 0.91
Cyr61/CCN1 and CTGF/CCN2 mediate the proangiogenic activity of VHL-mutant renal carcinoma cells. Carcinogenesis (2008) 0.91
Akt3 controls vascular endothelial growth factor secretion and angiogenesis in ovarian cancer cells. Int J Cancer (2011) 0.83
Drosophila von Hippel-Lindau tumor suppressor gene function in epithelial tubule morphogenesis. Mol Cell Biol (2010) 0.82
Drosophila VHL tumor-suppressor gene regulates epithelial morphogenesis by promoting microtubule and aPKC stability. Development (2010) 0.82
EGF-dependent and independent activation of MAP kinase during Drosophila oogenesis. Anat Rec A Discov Mol Cell Evol Biol (2003) 0.81
Developmental expression pattern of D-ets4, the Drosophila homologue of human Pdef. Gene Expr Patterns (2004) 0.79
Notch signaling during development requires the function of awd, the Drosophila homolog of human metastasis suppressor gene Nm23. BMC Biol (2014) 0.78
Characterization of fungal and bacterial components in gut/fecal microbiome. Curr Drug Metab (2015) 0.77
Interaction between Nm23 and the tumor suppressor VHL. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.76